To include your compound in the COVID-19 Resource Center, submit it here.

Sobi springboards U.S. growth in deal for AZ's Synagis

Swedish Orphan Biovitrum AB (SSE:SOBI) obtained U.S. rights to commercialize infectious disease drug Synagis palivizumab from AstraZeneca plc (LSE:AZN; NYSE:AZN) for $1.5 billion up front. Sobi called the deal, which also includes profit sharing with the pharma for MEDI8897, a stepping stone

Read the full 421 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE